Senseonics gains expanded Medicare coverage for implantable CGM

Three Medicare Administrative Contractors will start covering the Eversense E3 CGM for people who only take basal insulin.

Medicare will start covering Senseonics’ implantable continuous glucose monitor (CGM) for a broader group of patients in late February.
Three Medicare Administrative Contractors (MACs) — Noridian, Palmetto and National Government Services — finalized local coverage determinations that would cover the devices for people who only take basal insulin, or who don’t take insulin but have a history of hypoglycemia. Previously, they would only cover the CGM for people who took multiple shots of insulin per day.
Senseonics’ Eversense E3 CGM is implanted under the skin, and it lasts for up to six months. Ascensia is the exclusive global distributor for the device.

Sign up for Blog Updates